Trial Profile
A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients with Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Dexamethasone; Mercaptopurine; Methotrexate; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms EWALL INO
- 08 Feb 2023 Planned End Date changed from 1 Oct 2021 to 1 Jun 2024.
- 08 Feb 2023 Planned primary completion date changed from 1 Oct 2021 to 1 Jun 2023.
- 08 Feb 2023 Status changed from recruiting to active, no longer recruiting.